FOLD - Amicus Therapeutics, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue4,958-1,224
Cost of Revenue833--
Gross Profit4,125-1,224
Operating Expenses
Research Development104,79376,94347,624
Selling General and Administrative77,91151,64620,817
Non Recurring6915-63
Total Operating Expenses186,015130,43769,925
Operating Income or Loss-181,890-130,437-68,701
Income from Continuing Operations
Total Other Income/Expenses Net-16,493-103146
Earnings Before Interest and Taxes-198,383-130,540-68,555
Interest Expense5,3981,5781,484
Income Before Tax-203,781-132,118-70,039
Income Tax Expense-3,739--1,113
Minority Interest---
Net Income From Continuing Ops-200,042-132,118-68,926
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-200,042-132,118-68,926
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-200,042-132,118-68,926